This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chu, R. L. Articles by Van Meir, E. G. Search for Related Content PubMed PubMed Citation Articles by Chu, R. L. Articles by Van Meir, E. G. Related Collections Therapeutics and Targets Therapeutics and Targets: Experimental Therapeutics– Biologics Clinical Research: Clinical Trials

Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer

¹ Laboratory of Molecular Neuro-Oncology, Departments of Neurosurgery, Hematology/Oncology, and Winship Cancer Institute, and ² AFLAC Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University, Atlanta, Georgia

Oncolytic virotherapy is the use of genetically engineered viruses that specifically target and destroy tumor cells via their cytolytic replication cycle. Viral-mediated tumor destruction is propagated through infection of nearby tumor cells by the newly released progeny. Each cycle should amplify the number of oncolytic viruses available for infection. Our understanding of the life cycles of cytolytic viruses has allowed manipulation of their genome to selectively kill tumor cells over normal tissue. Because the mechanism of tumor destruction is different, oncolytic virotherapy should work synergistically with current modes of treatment such as chemotherapy and radiation therapy. This article focuses on oncolytic adenoviruses that have been created and tested in preclinical and clinical trials in combination with chemotherapy, radiation therapy, and gene therapy.

This article has been cited by other articles:

				E. V. Shashkova, K. Doronin, J. S. Senac, and M. A. Barry Macrophage Depletion Combined with Anticoagulant Therapy Increases Therapeutic Window of Systemic Treatment with Oncolytic Adenovirus Cancer Res., July 15, 2008; 68(14): 5896 - 5904. [Abstract] [Full Text] [PDF]

				V. Dixit and R. L. Juliano Selective Killing of Smad4-Negative Tumor Cells via a Designed Repressor Strategy Mol. Pharmacol., July 1, 2008; 74(1): 289 - 297. [Abstract] [Full Text] [PDF]

				J. R. Radke, Z. K. Siddiqui, T. A. Miura, J. M. Routes, and J. L. Cook E1A Oncogene Enhancement of Caspase-2-Mediated Mitochondrial Injury Sensitizes Cells to Macrophage Nitric Oxide-Induced Apoptosis J. Immunol., June 15, 2008; 180(12): 8272 - 8279. [Abstract] [Full Text] [PDF]

				S. Akai, H. Hosomi, K. Minami, K. Tsuneyama, M. Katoh, M. Nakajima, and T. Yokoi Knock Down of {gamma}-Glutamylcysteine Synthetase in Rat Causes Acetaminophen-induced Hepatotoxicity J. Biol. Chem., August 17, 2007; 282(33): 23996 - 24003. [Abstract] [Full Text] [PDF]

				D. E. Post, E. M. Sandberg, M. M. Kyle, N. S. Devi, D. J. Brat, Z. Xu, M. Tighiouart, and E. G. Van Meir Targeted Cancer Gene Therapy Using a Hypoxia Inducible Factor Dependent Oncolytic Adenovirus Armed with Interleukin-4 Cancer Res., July 15, 2007; 67(14): 6872 - 6881. [Abstract] [Full Text] [PDF]

				M. Wakayama, M. Abei, R. Kawashima, E. Seo, K. Fukuda, H. Ugai, T. Murata, N. Tanaka, I. Hyodo, H. Hamada, et al. E1A, E1B Double-Restricted Adenovirus with RGD-Fiber Modification Exhibits Enhanced Oncolysis for CAR-Deficient Biliary Cancers Clin. Cancer Res., May 15, 2007; 13(10): 3043 - 3050. [Abstract] [Full Text] [PDF]

				J. Leja, H. Dzojic, E. Gustafson, K. Oberg, V. Giandomenico, and M. Essand A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy Clin. Cancer Res., April 15, 2007; 13(8): 2455 - 2462. [Abstract] [Full Text] [PDF]

				K. Mantwill, N. Kohler-Vargas, A. Bernshausen, A. Bieler, H. Lage, A. Kaszubiak, P. Surowiak, T. Dravits, U. Treiber, R. Hartung, et al. Inhibition of the Multidrug-Resistant Phenotype by Targeting YB-1 with a Conditionally Oncolytic Adenovirus: Implications for Combinatorial Treatment Regimen with Chemotherapeutic Agents. Cancer Res., July 15, 2006; 66(14): 7195 - 7202. [Abstract] [Full Text] [PDF]

				J. Zhou, Q. Gao, G. Chen, X. Huang, Y. Lu, K. Li, D. Xie, L. Zhuang, J. Deng, and D. Ma Novel Oncolytic Adenovirus Selectively Targets Tumor-Associated Polo-Like Kinase 1 and Tumor Cell Viability Clin. Cancer Res., December 1, 2005; 11(23): 8431 - 8440. [Abstract] [Full Text] [PDF]

				C. Springfeld, V. von Messling, C. A. Tidona, G. Darai, and R. Cattaneo Envelope Targeting: Hemagglutinin Attachment Specificity Rather than Fusion Protein Cleavage-Activation Restricts Tupaia Paramyxovirus Tropism J. Virol., August 15, 2005; 79(16): 10155 - 10163. [Abstract] [Full Text] [PDF]

				D. E. Post, N. S. Devi, Z. Li, D. J. Brat, B. Kaur, A. Nicholson, J. J. Olson, Z. Zhang, and E. G. Van Meir Cancer Therapy with a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors Clin. Cancer Res., December 15, 2004; 10(24): 8603 - 8612. [Abstract] [Full Text] [PDF]